Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and ¹³¹I activity in patients with thyroid cancer and low risk of recurrence
- PMID: 20954820
- DOI: 10.1089/thy.2010.0145
Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and ¹³¹I activity in patients with thyroid cancer and low risk of recurrence
Abstract
Background: This study investigated the value of postoperative stimulated thyroglobulin (Tg) combined with neck ultrasonography for the prediction of the posttherapy whole-body scanning (RxWBS) and the efficacy of ablation with 30 mCi ¹³¹I in patients with thyroid cancer and low risk of recurrence to identify those who do not require ablation or only need a low ¹³¹I activity.
Methods: A total of 237 consecutive patients with well-differentiated thyroid cancer and low risk of recurrence who were initially treated by total thyroidectomy followed by remnant ablation with 1.1 or 3.7 GBq (30 or 100 mCi) ¹³¹I were studied. Neck ultrasonography, Tg after levothyroxine withdrawal, and anti-Tg antibodies (TgAb) were obtained before, and RxWBS was performed 7 days after ¹³¹I administration. Patients with TgAb were excluded.
Results: Postoperative ultrasonography revealed lymph node metastases in 5/237 (2%) patients. RxWBS showed ectopic uptake in 3/232 (1.3%) patients with negative ultrasonography. The negative predictive value of postoperative stimulated Tg <1 ng/mL (n = 132) or <10 ng/mL (n = 213) combined with negative ultrasonography was 100%. Among patients with detectable postoperative stimulated Tg <10 ng/mL and negative ultrasonography, 50 received 1.1 GBq ¹³¹I and 31 received 3.7 GBq. In the control assessment, stimulated Tg <1 ng/mL and neck ultrasonography without anomalies were achieved in 47/50 (94%) and in 29/31 patients (93.5%). All patients with stimulated Tg ≤1 ng/mL, negative TgAb, and normal ultrasonography before ablation continued to show the same results 8-12 months after initial therapy as expected, irrespective of the administration of 1.1 GBq (n = 82) or 3.7 GBq ¹³¹I (n = 50).
Conclusions: Measurement of stimulated Tg combined with neck ultrasonography after total thyroidectomy may exclude the need for ablation in 56% of low-risk patients without TgAb (Tg <1 ng/mL) and permit the administration of an activity of 1.1 GBq ¹³¹I in another 34% with low Tg levels.
Comment in
-
Ruling out 131I ablation in low-risk differentiated thyroid carcinoma basing on thyroglobulin measurement.Thyroid. 2011 Jul;21(7):809-10; author reply 811-2. doi: 10.1089/thy.2010.0435. Epub 2011 May 26. Thyroid. 2011. PMID: 21615306 No abstract available.
-
Stimulated thyroglobulin and neck ultrasonography facilitates postsurgical radioactive iodine remnant ablation selection in patients with low-risk well-differentiated thyroid carcinoma.Thyroid. 2012 Jul;22(7):760-1. doi: 10.1089/thy.2011.0453. Epub 2012 Jun 4. Thyroid. 2012. PMID: 22663549 No abstract available.
Similar articles
-
Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.Thyroid. 2012 Nov;22(11):1165-9. doi: 10.1089/thy.2012.0026. Epub 2012 Oct 10. Thyroid. 2012. PMID: 23050784
-
The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.Thyroid. 2012 Feb;22(2):113-6. doi: 10.1089/thy.2011.0020. Epub 2012 Jan 6. Thyroid. 2012. PMID: 22224815
-
Value of repeat stimulated thyroglobulin testing in patients with differentiated thyroid carcinoma considered to be free of disease in the first year after ablation.Thyroid. 2012 May;22(5):482-6. doi: 10.1089/thy.2011.0214. Epub 2011 Dec 16. Thyroid. 2012. PMID: 22175271
-
Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level.Endocr Relat Cancer. 2011 Mar 3;18(2):R29-40. doi: 10.1677/ERC-10-0292. Print 2011 Apr. Endocr Relat Cancer. 2011. PMID: 21183629 Review.
-
Papillary thyroid cancer: medical management and follow-up.Curr Treat Options Oncol. 2005 Jul;6(4):323-38. doi: 10.1007/s11864-005-0036-8. Curr Treat Options Oncol. 2005. PMID: 15967085 Review.
Cited by
-
Predicting factors and clinical outcome of biochemical incomplete response in middle eastern differentiated thyroid carcinoma.Endocrine. 2024 May 2. doi: 10.1007/s12020-024-03844-x. Online ahead of print. Endocrine. 2024. PMID: 38696058
-
Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment.Arch Endocrinol Metab. 2024 Apr 4;68:e220506. doi: 10.20945/2359-4292-2022-0506. Arch Endocrinol Metab. 2024. PMID: 38578436 Free PMC article.
-
The value of the first postoperative diagnostic I-131 scan in patients with papillary thyroid carcinoma.J Cancer Res Clin Oncol. 2024 Feb 6;150(2):80. doi: 10.1007/s00432-023-05581-6. J Cancer Res Clin Oncol. 2024. PMID: 38319395 Free PMC article.
-
Establishing a Cutoff Serum Thyroglobulin Value for the Diagnosis and Management of Well-Differentiated Thyroid Cancer.World J Nucl Med. 2023 Sep 6;22(3):208-216. doi: 10.1055/s-0043-1771286. eCollection 2023 Sep. World J Nucl Med. 2023. PMID: 37854090 Free PMC article.
-
Combination of Stimulated Thyroglobulin and Antithyroglobulin Antibody Predicts the Efficacy and Prognosis of 131I Therapy in Patients With Differentiated Thyroid Cancer Following Total Thyroidectomy: A Retrospective Study.Front Endocrinol (Lausanne). 2022 Apr 6;13:857057. doi: 10.3389/fendo.2022.857057. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35464061 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous